Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)

BACKGROUND: In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced significantly less physical functional decline with 24‐week edaravone vs placebo, followed by open‐label treatment for an additional 24 weeks. METHODS: Outcome (the change in ALS Functional Rating Scale–Revised,...

Descripción completa

Detalles Bibliográficos
Autores principales: Shefner, Jeremy, Heiman‐Patterson, Terry, Pioro, Erik P., Wiedau‐Pazos, Martina, Liu, Shawn, Zhang, Jeffrey, Agnese, Wendy, Apple, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Research Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004197/
https://www.ncbi.nlm.nih.gov/pubmed/31621933
http://dx.doi.org/10.1002/mus.26740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004197/
https://www.ncbi.nlm.nih.gov/pubmed/31621933
http://dx.doi.org/10.1002/mus.26740

Ejemplares similares